Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | melanocortin 4 receptor | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 3, subfamily A, polypeptide 4 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 3, subfamily A, polypeptide 4 | 502 aa | 492 aa | 24.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0.012 | 0.012 |
Brugia malayi | Nucleoside transporter family protein | 0.0079 | 0.6494 | 1 |
Entamoeba histolytica | nucleoside transporter, putative | 0.0079 | 0.6494 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0015 | 0.012 | 0.0185 |
Onchocerca volvulus | Equilibrative nucleoside transporter, putative homolog | 0.0079 | 0.6494 | 0.5 |
Leishmania major | acidocalcisomal exopolyphosphatase, putative | 0.0114 | 1 | 1 |
Echinococcus multilocularis | equilibrative nucleoside transporter 3 | 0.0079 | 0.6494 | 1 |
Trichomonas vaginalis | equilibrative nucleoside transporter, putative | 0.0079 | 0.6494 | 1 |
Leishmania major | cytochrome p450-like protein | 0.0015 | 0.012 | 0.012 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0015 | 0.012 | 0.0185 |
Trypanosoma cruzi | exopolyphosphatase | 0.0114 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0079 | 0.6494 | 1 |
Trichomonas vaginalis | equilibrative nucleoside transporter, putative | 0.0079 | 0.6494 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.6494 | 1 |
Trypanosoma brucei | exopolyphosphatase | 0.0114 | 1 | 1 |
Plasmodium falciparum | conserved Plasmodium protein, unknown function | 0.0039 | 0.249 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0114 | 1 | 1 |
Trypanosoma brucei | cytochrome P450, putative | 0.0015 | 0.012 | 0.012 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0015 | 0.012 | 0.5 |
Onchocerca volvulus | Equilibrative nucleoside transporter, putative homolog | 0.0079 | 0.6494 | 0.5 |
Echinococcus multilocularis | equilibrative nucleoside transporter protein | 0.0079 | 0.6494 | 1 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0015 | 0.012 | 0.012 |
Schistosoma mansoni | hypothetical protein | 0.0114 | 1 | 1 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0015 | 0.012 | 0.0185 |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.6494 | 1 |
Brugia malayi | hypothetical protein | 0.0079 | 0.6494 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0015 | 0.012 | 0.0185 |
Schistosoma mansoni | hypothetical protein | 0.0114 | 1 | 1 |
Trypanosoma cruzi | acidocalcisomal exopolyphosphatase, putative | 0.0114 | 1 | 1 |
Trichomonas vaginalis | equilibrative nucleoside transporter, putative | 0.0079 | 0.6494 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0015 | 0.012 | 0.0185 |
Trichomonas vaginalis | equilibrative nucleoside transporter, putative | 0.0079 | 0.6494 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.6494 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 53 nM | Antagonist activity at human MC4R expressed in HEK293 cells by cAMP acumulation assay | ChEMBL. | 17822895 |
IC50 (functional) | = 53 nM | Antagonist activity at human MC4R expressed in HEK293 cells by cAMP acumulation assay | ChEMBL. | 17822895 |
IC50 (ADMET) | = 2300 nM | Inhibition of microsomal CYP3A4 | ChEMBL. | 17822895 |
IC50 (ADMET) | = 2300 nM | Inhibition of microsomal CYP3A4 | ChEMBL. | 17822895 |
Ki (binding) | = 2.4 nM | Binding affinity at human MC4R | ChEMBL. | 17822895 |
Ki (binding) | = 2.4 nM | Binding affinity at human MC4R | ChEMBL. | 17822895 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.